News und Analysen

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA^® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the

ICON plc, (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, will host its 2024 Investor Day today in New York City. The event will feature presentations

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024.

Aurinia

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core⁽¹⁾ compared to the second quarter

Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024, at approximately 9:00 a.m. (ET) at

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth

Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000^® Index at the conclusion of Russell Investments’ annual reconstitution of its

Regulatory News:

Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Novocure (NASDAQ: NVCR) hat heute die ersten Wirksamkeits- und Sicherheitsdaten der TIGER-Studie veröffentlicht, die den Einsatz der Therapie mit Tumor Treating Fields (TTFields) in der klinischen

Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual